RxDoctor Payments Data

Douglas Starr, MD

Family Medicine · Diamond Bar, CANPI 1154322998

Payments from drug & device makers

$1,055in general payments, 2019–2025

Across 60 payments — averaging $17.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$238
  • GSK$131
  • Novo Nordisk$104
  • Merck$82
  • Amgen$79
  • Biohaven Pharmaceutical Holding Company Ltd.$78
  • plus $344 from 9 others

What the payments were for

  • Consulting fees$202%
  • Food & beverage$1,03598%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,055 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$127,977
Medicare patients
259
Services billed
1,774

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban150$121,677
JardianceEmpagliflozin78$88,607
JanuviaSitagliptin Phosphate47$63,455
OzempicSemaglutide39$49,958
TradjentaLinagliptin49$42,451
FarxigaDapagliflozin Propanediol42$37,892
XareltoRivaroxaban21$27,159
TrulicityDulaglutide14$15,492
MyrbetriqMirabegron15$14,711
EntrestoSacubitril/Valsartan15$13,707
Breo ElliptaFluticasone/Vilanterol16$12,780
LivaloPitavastatin Calcium21$11,799
MounjaroTirzepatide11$11,223
Fluticasone-SalmeterolFluticasone Propion/Salmeterol22$7,531
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$7,096

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$56$121,677150 claims
MerckJanuvia$82$63,45547 claims
Novo NordiskOzempic$104$49,95839 claims
AstraZenecaFarxiga$68$37,89242 claims
Lilly USA, LLCTrulicity, Mounjaro$238$26,71525 claims
NovartisEntresto$32$13,70715 claims
GSKBreo Ellipta$131$12,78016 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$29$6,68113 claims
AbbVieSynthroid$68$3,00937 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Diamond Bar

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →